The Manufacturers Life Insurance Company Purchases Shares of 13,551 LifeMD, Inc. (NASDAQ:LFMD)

The Manufacturers Life Insurance Company acquired a new position in shares of LifeMD, Inc. (NASDAQ:LFMD) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,551 shares of the company’s stock, valued at approximately $93,000.

A number of other large investors have also made changes to their positions in the stock. Hussman Strategic Advisors Inc. acquired a new stake in LifeMD during the first quarter worth about $432,000. Thompson Davis & CO. Inc. grew its holdings in shares of LifeMD by 182.8% during the 1st quarter. Thompson Davis & CO. Inc. now owns 40,000 shares of the company’s stock worth $411,000 after purchasing an additional 25,855 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of LifeMD by 251.0% during the first quarter. Russell Investments Group Ltd. now owns 64,927 shares of the company’s stock valued at $667,000 after purchasing an additional 46,428 shares during the period. Blair William & Co. IL acquired a new position in shares of LifeMD in the first quarter valued at $642,000. Finally, Vanguard Group Inc. raised its stake in shares of LifeMD by 12.5% in the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after purchasing an additional 128,701 shares in the last quarter. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Stock Up 2.2 %

LFMD opened at $4.68 on Monday. The firm’s 50-day simple moving average is $5.04 and its 200-day simple moving average is $7.10. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.83 and a current ratio of 0.87. LifeMD, Inc. has a twelve month low of $4.10 and a twelve month high of $12.88. The firm has a market cap of $195.42 million, a price-to-earnings ratio of -6.32 and a beta of 1.18.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The business had revenue of $50.66 million for the quarter, compared to analysts’ expectations of $48.47 million. During the same quarter in the previous year, the business posted ($0.23) EPS. Equities research analysts anticipate that LifeMD, Inc. will post -0.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LFMD has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price target on shares of LifeMD in a research note on Friday, September 20th. KeyCorp decreased their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, B. Riley assumed coverage on shares of LifeMD in a research note on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $12.00.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.